Takeda in talks to buy rival Nycomed

Click to follow
The Independent Online

Japan's largest drug maker Takeda Pharmaceutical is in talks to buy its privately held Swiss rival Nycomed for more than $12bn (£7bn) in an attempt to extend its global reach into Europe and emerging markets.

The purchase would offer the mainly Asia and US-focused maker of drugs for diabetes and heart disease access to a lung disease drug, Daxas, just approved in the United States, and a portfolio of over-the-counter consumer products.

A Nycomed deal would be Japan's second-biggest overseas takeover according to Thomson Reuters data – after Japan Tobacco's $19bn buy of Britain's Gallagher – and would be a second major deal for Takeda after it bought the US cancer drug specialist Millennium Pharmaceuticals in 2008 for about $9bn.